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Microsomal liver function declines steadily after kidney grafting: A
three to five year follow-up. We have previously shown that the
functioning hepatocyte mass (galactose elimination capacity, GEC) and
microsomal liver functions (non-renal clearances of unbound pred-
nisolone and cyclosporin A) are impaired in renal allograft recipients (N
= 28) one month and one year after successful transplantation. To
assess the natural history of these hepatic functional derangements, we
reinvestigated 21 patients with stable renal function three to five years
following grafting. GEC remained with 6.07 0.86 mgtmin x kg
significantly (P < 0.001) below that in healthy controls (7.52 0.78
mg/mm x kg), but did not significantly change during follow-up (5.93
0.96 and 6.26 0.94mg/mm x kg at 1 year and I month, respectively).
In contrast, the non-renal clearance of unbound prednisolone declined
steadily during follow-up averaging 4.98 0.71 mI/mm X kg at three to
five (compared to 5.83 1.51 and 6.80 1.73 mI/mm x kg at one year
and one month, respectively). These values were lower (P < 0.01) than
those observed in healthy control subjects (7.56 1.59 mI/mm x kg).
The total body clearance of cyclosporin A decreased similarly with time
averaging 4.5 1.2 mI/mm x kg at three to five years (compared to 4.9
1.2 and 5.9 2.1 mllmin X kg at 1 year and 1 month, respectively).
In conclusion: 1) the functioning hepatocyte mass and microsomal liver
functions are markedly impaired in renal allograft recipients; 2) mi-
crosomal liver functions, but not the functioning hepatocyte mass,
steadily decline with time during three to five years after transplanta-
tion, despite the absence of clinical and (routine) laboratory evidence of
significant liver disease and excellent graft function.
The European Dialysis and Transplant Association [11 re-
ported in 1983 that liver failure accounts for 8.6% of all deaths
in patients with a functioning renal transplant. In 1985, Weir,
Kirkman and Strom [21 found that hepatic failure was the
leading cause of death in renal transplant recipients whose renal
allografts had functioned for more than five years at Brigham
and Women's Hospital in Boston. Factors thought to contribute
to this high incidence of liver failure in patients with stable renal
allografts include simultaneous affection of liver and kidneys by
the underlying disease process, such as in polycystic disease,
and the immunosuppressive drug therapy exhibiting recognized
hepatotoxic potential and facilitating the spread of hepatotropic
viruses, such as hepatitis B virus (HBV) and cytomegalovirus
(CMV), respectively [3—11]. Little is known regarding the time
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course of the development of liver failure following kidney
transplantation.
In a recent study [12] we showed by quantitative assessment
of the activities of microsomal (clearance of prednisolone and
cyclosporin A [13, 14]) and cytosolic (galactose elimination
capacity [15]) liver enzymes a steady decline in liver function
from one month to one year after successful renal transplanta-
tion. To define the later course of this hepatic functional
derangement we restudied the same transplant patients three to
five years after grafting. This report, therefore, updates and
extends our previous published observations [12], and summa-
rizes changes in liver function following kidney transplantation
over a three to five year period.
Methods
Patients
Twenty-eight consecutive renal transplant patients were orig-
inally investigated one month and one year after successful
kidney transplantation [12]. Patients with diabetes or polycystic
disease were excluded. End-stage renal disease had been due to
glomerulonephritis in 13, interstitial nephritis associated with
analgesic abuse in 9, interstitial nephritis without analgesic
abuse in 4 and hypertension in 2 patients, respectively. Twenty-
one out of the 28 original patients were reinvestigated three to
five years after transplantation (Table 1). Seven patients could
not be reinvestigated at three to five years because they refused
to participate [professional stress (1 patient), status after coro-
nary bypass surgery (1)] or the investigators considered the
patient's status inappropriate for the study [lack of peripheral
veins (2), infectious disease (1), transplant rejection after non-
compliance with the prescribed immunosuppressive therapy (1)
or death from urinary bladder cancer (1)]. The seven patients
not reinvestigated at three to five years after transplantation had
glomerulonephritis (2 patients), interstitial nephritis with (4) or
without (1) analgesic abuse. All patients reinvestigated had a
stable renal transplant as judged by creatinine clearance (Table
1).
All patients were initially treated with cyclosporin A (CsA)
and prednisone. CsA was given as a single daily dose. The daily
dose was chosen in order to obtain whole blood concentra-
tions—assessed 24 hours after the last dose—between 300 and
600 ng/ml as determined by RIA using a polyclonal antibody
[16]. Each sample was assayed in duplicate using cyclosporine
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Table 1. Clinical and laboratory data of the transplant patients studied at 1 month, 1 year and 3 to 5 years after transplantation
Transplant patients
P values
1 month vs.
1 year
1 year vs.
3—5 years
1 month vs.
3—5 years1 month 1 year 3—5 years
N patients (females/males) 28 (14/14) 28 (14/14) 21(11/10) — — —
Age years 49 10 50 10 53 10 — — —
Body weight kg 61.7 10.0 70.1 11.8 72 13.2 <0.001 NS <0.001
Albumin glliter 31.8 5.2 34.2 3.3 35.0 2.8 <0.05 NS <0.01
Transcortin mg/liter 32.9 4.0 43.1 8.0 36.0 6.0 <0.001 <0.001 NS
ASAT U/liter 23.6 24.8 17.0 13.9 10.2 5.0 NS <0.05 <0.01
Alkaline phosphatase U/liter 53.3 36.2 82.7 42.5 52.2 27.8 <0.01 <0.01 NS
5'-Nucleotidase U/liter 6.3 1.4 8.1 4.2 7.3 2.1 <0.05 NS NS
Total serum bilirubjn amol/liter 9.0 3.1 10.6 6.4 11.4 5.4 NS NS NS
Serum creatinine ismol/liter 136 49 138 32 133 26 NS NS NS
Ccr ml/min/1.73 m2 47 18 56 17 60 18 NS NS <0.05
RIA kits supplied by the manufacturer (Sandoz, Paris, France).
At one month, the mean blood concentration of CsA was 560
200 ng/ml, at one year 400 170 ng/ml, and after three to five
years 362 127 ng/ml. The corresponding mean daily doses of
CsA were 573 200 at one month, 411 166 at one year, and
308 131 mg at three to five years. The mean dose of
prednisone at one month was 25 9 mg per day. Whenever
possible the dose of prednisone was tapered off in the course of
the first year. After one year 17 of 28 and after three to five
years 12 of 21 patients were still on prednisone (mean daily
dose: 3.9 5.3 mg and 5.2 4.2 mg, respectively). In addition
the following drugs were prescribed: furosemide (15 patients at
1 month/il patients at 1 year/2 patients at 3 to 5 years), atenolol
(8/16/8), propranolol (2/1/1), metoprolol (1/0/1), nifedipine (9/12/
8), verapamil (1/0/0), minoxidil (1/2/0), ranitidine (26/20/3),
diazepam (3/0/1), and flurazepam (4/0/1).
The average ASAT and total bilirubin levels were within the
respective normal range throughout the entire follow-up period
(Table 1). A slight increase in the alkaline phosphatase (<2 X
upper limit) was observed in seven patients between the first
and the second investigation. After three to five years only one
of these seven patients had a slightly increased alkaline phos-
phatase. In another patient the activity of the alkaline phos-
phatase increased markedly from 350 to 1250 units per liter
between the first and the second investigation and completely
normalized at three to five years. The values from the latter
patient were excluded from the calculation of the mean values
in Table 1. In seven of the initial eight patients with increased
alkaline phosphatase activities, serum bilirubin concentrations
and activities of 5'-riucleotidase did not increase concomitantly
with the values of the alkaline phosphatase, suggesting rather a
bony than hepatic origin of this alkaline phosphatase [17]. Three
patients were positive for hepatitis B virus antigens and a fourth
patient had antibodies against hepatitis B surface antigen. In
one patient (positive for hepatitis Be antigen), the activities of
alkaline phosphatase, 5'-nucleotidase, ASAT and ALAT were
normal at one month after transplantation but elevated (<3 x
upper limit) at one year and three to five years, and in another
patient (positive for hepatitis Bs antigen) ASAT and ALAT
were elevated without evidence of cholestasis on all occasions,
suggesting chronic hepatitis. The second patient positive for
hepatitis s antigen and the patient with antibodies against
hepatitis s antigen had normal liver enzymes throughout the
study. In four patients, ALAT activities were elevated (<2x
upper limit) one month but not one year and three to five years
after transplantation. None of the patients had evidence of
CMV infection during the entire follow-up period.
Control subjects
Prednisone and prednisolone metabolism was studied in 28
healthy volunteers, who were not on chronic drug therapy,
according to the protocol given below. Part of the results of this
investigation has been previously reported [18—201. These vol-
unteers had normal liver enzymes and normal renal function.
Their plasma concentrations of albumin (41 4 g/liter) were
higher (P < 0.001) than in renal transplant patients (Table 1).
The mean transcortin concentration was higher in the controls
(40 8 mg/liter) than in the patients at one month (P < 0.001)
and at three to five years (P < 0.05) but not at one year after
transplantation (Table 1). Although covering a similar age
range, the mean (± SD) age was lower (P < 0.05) in the healthy
controls (34 15 years; range 23 to 68 years) than in the renal
transplant patients (at I month: 49 10 years; range 25 to 65
years). Galactose elimination capacity (GEC) was measured in
another group of 28 healthy volunteers. Part of the results of
this investigation has been previously reported [21, 22]. While
again covering a similar age range, these control subjects were
also on average slightly younger (42 15 years; range 23 to 71
years; P < 0.05) than the renal transplant patients. For ethical
reasons, no control group of healthy subjects given CsA was
established.
Protocol
Informed consent was obtained before initiation of the study.
The study was approved by the Committee on Human Research
at our institution. Each patient was investigated according to
the same protocol one month, one year and three to five years
after transplantation on three separate days.
Day 1. An i.v. bolus dose of 0.8 mg per kg body weight of
prednisolone (Codesol'; Merck, Sharp and Dohme, West
Point, Pennsylvania, USA) and concomitantly an oral dose of
15 mg per kg body weight of CsA (Sandoz, Basel, Switzerland)
were given, starting around 8 a.m.
Day 2. An oral dose of 0.8 mg per kg body weight of
prednisone was administered together with an i.v. dose of CsA
(5 mg per kg body wt). In each patient the sequence of the study
days 1 and 2 was chosen at random for the investigation at one
month, but kept the same for the later investigations. The i.v.
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dose of CsA (diluted in 250 ml of 5% glucose) was infused over
60 minutes into a peripheral vein. Both studies were started
after a fasting for about 10 hours. Immediately after oral dosing,
all subjects received 100 ml milk. On both study days, the
patients were given a breakfast two hours after drug adminis-
tration. Venous blood samples were obtained before the oral
and i.v. dose and after 5, 15, 30, 60, 90, 120, 240, 360, 540, 780
(i.v. dose only), 900 (oral dose only) and 1,440 minutes. The
anticoagulant used was EDTA. Plasma was stored at —30°C. In
addition, 24-hour urine collections (controlled by urine creati-
nine measurements) were obtained on both study days.
Day 3. An i.v. bolus dose of galactose (0.5 g per kg body wt)
was injected into a peripheral vein over five minutes and
heparinized blood samples collected before dosing and 20, 25,
30, 35, 40, 45, 50, 55 and 60 minutes thereafter. Urine was
collected for four hours. No patient with recent alcohol intake
was investigated. In case of doubt, an analysis of blood alcohol
concentration was performed.
Analytical methods
Serum concentrations/activities of bilirubin, albumin, creati-
nine, ALAT, ASAT, 5'-nucleotidase and alkaline phosphatase
were determined in the central hospital laboratory according to
standard methods. Serum transcortin concentrations were mea-
sured by electroimmunodiffusion [23]. Plasma samples were
analyzed for prednisolone and prednisone by a previously
described HPLC procedure [24]. The intraday variability coef-
ficient of variation (CV) of this method is 1 to 4%, the interday
CV 2.8 to 10.6% [24]. Equilibrium dialysis was performed to
quantify the concentration of unbound prednisolone in plasma
as described [25]. Because of the concentration-dependent
protein binding of prednisolone, protein binding was deter-
mined in each plasma sample from each subject. The intraday
variability for the protein binding measurements was found to
be 1.2%, the interday variability 1.6%. The in vitro fraction of
unbound prednisolone was calculated by dividing the concen-
tration in the buffer half-cell by the concentration in the plasma
half-cell. Because prednisolone protein binding is nonlinear, it
is necessary to correct the binding parameter for the changes in
concentration that are caused by diffusion from plasma into
buffer during equilibrium dialysis. This was done by the method
of Behm and Wagner [26]. Prednisolone, prednisone and 613-
hydroxyprednisolone were assessed in urine using a previously
described HPLC procedure [27, 28] exhibiting an intraday CV
of 5.5 to 10.9% and an interday CV of 4.5 to 11.6% [27].
Measurements of GsA in whole blood
Each blood sample was analyzed for CsA by HPLC. The
extraction procedure was performed according to Sawchuck
and Carter [29] with a slight modification to improve the
recovery [30]. The HPLC procedure was performed according
to Nussbaumer, Niederberger and Keller [31]. This method has
an intraday variability of 2.2% at a high concentration (500
mg/mI) and of 11.9% at a low concentration (50ng/ml, N = 10)
[30], and an interday variability of 8.8% (500 ng/ml) and 10.3%
(50 ng/ml), respectively [30].
Galactose was measured enzymatically in plasma and urine,
as described [32]. The CV for paired observations was 5.2%
[21].
Calculations
The area under the plasma concentration versus time curve
(AUC) was calculated for total prednisolone, total prednisone,
unbound prednisolone and CsA using the linear trapezoidal rule
and extrapolation to infinity [33]. The remaining AUC beyond
the last measured data point was estimated by dividing the last
plasma concentration by the terminal disposition rate constant.
Calculations of the AUCs were performed by subtracting the
residual AUC resulting from the previous dose. The terminal
disposition rate constant was calculated by dividing in 2 by the
terminal half-life which was derived graphically. Total body
clearance values for total and unbound prednisoione and for
CsA were calculated by dividing the i.v. dose by the corre-
sponding AUC. Renal clearance values of prednisoione were
calculated by dividing the amount of prednisolone recovered in
the urine by the corresponding AUC of total or unbound
prednisolone. An estimate of the fractional renal clearance of
prednisolone was derived by dividing the renal clearance of
prednisolone by the glomerular filtration rate as assessed by the
creatinine clearance. Nonrenal clearance (metabolic clearance)
values were obtained by subtracting renal clearance from total
body clearance values. The volume of distribution at steady
state and the mean residence time were calculated by a non-
compartmental method [34, 35]. The systemic availability of
prednisolone after oral prednisone was calculated by dividing
the AUC of prednisolone after the administration of oral
prednisone by the corresponding AUC after i.v. prednisolone.
The GEC was calculated as the amount of galactose injected
minus the amount of galactose recovered in urine, divided by
the extrapolated time when the galactose plasma concentration
would become zero. For this extrapolation, zero-order kinetics
were assumed, and a correction for uneven distribution of
galactose was used as proposed by Tygstrup [36].
Statistical analysis
The three follow-up periods were compared with a computer
based Ryan-Einot-Gabriel-Welsch-Test. When this test indi-
cated a significant difference between periods a Student's t-test
for unpaired or paired observations was performed. Differences
were considered significant at the level of P < 0.05. All the
values are given as mean SD.
Results
In all patients prednisoione and prednisone concentrations
were measured simultaneously in plasma after an oral dose of
prednisone and an i.v. bolus dose of prednisolone. The mean
total body clearance of prednisolone derived from the i.v. bolus
dose study was lower in renal transplant patients on all three
occasions than in the control subjects whether calculated with
reference to total or unbound prednisolone, respectively (Table
2). Moreover, these clearance values decreased between one
month and one year after transplantation, and a further decline
was observed after three to five years (Table 2, Fig. 1). The
lower total body clearance values of prednisolone in renal
transplant patients than in control subjects were due to lower
renal and non-renal clearances (Table 2). The decline of the
total body clearance value in the course of the first three to five
years of successful renal transplantation was almost entirely
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Table 2. Pharmacokinetic parameters in renal transplant (RT) patients 1 month, 1 year and 3 to 5 years after transplantation and in control
subjects (CS)
Control subjects
Transplant patients
I month 1 year 3—5 years
N subjects 28 28 28 21
Prednisolone
Total prednisolone
Total body clearance mi/mm x kg 2.71 0.43 2.13 0.34c 1.76 O.32cl' 1,53 0.l8"
Renal clearance mi/mm x kg 0.76 0.25 0.18 0.l2 0.14 0.08 0.12 0.06c
Fractional renal clearance 0.49 0.15 0.24 0.l4 0.20 0.12c 0.14 0.07'
Nonrenal clearance mi/mm x kg 1.94 0.34 1.98 0.28 1.61 O.3l 1.41 017c,f,h
Mean residence time mm 239 42 316 36C 312 55C 332 41C
Volume of distribution liter/kg 0.63 0.07 0.66 0.09 0.54 008b.f 0.51 0O9
Systemic availability % 72 10 85 l4 73 17" 73 l2
Unbound prednisolone
Total body clearance mi/mm x kg 10.6 2.22 7.30 2.06c 6.38 1,62c.d 539 0.72c'
Renal clearance mi/mm x kg 3.0 1.05 0.61 0.5lc 0.54 0.30c 0.41 0.l9c
Fractional renal clearance 2.04 0.58 0.76 0.43c 0.65 0.27c 0.50 022c..g
Nonrenal clearance mi/mm x kg 7.56 1.59 6.80 1.73" 5.83 l.5l'" 4.98 o,71g
Mean residence time mm 152 31 192 28C 201 35C 253
Volume of distribution liter/kg 1.57 0.29 1.42 0.37a 1.26 0.30 1.42
Systemic availability % 52 II 69 16C 54 2O 62 13C
Cyclosporin A
Clearance mI/mm x kg 5.9 2.1 4.9 1.2" 4.5 1.2
Volume of distribution liter/kg
Mean residence time mm
3.9 1.7
896 330
3.1 07d
736 196"
2.8 0.8717 l57
Systemic availability % 32.7 12.1 21.6 l.6 25.4 6.8e
Galactose
Galactose elimination capacity mg/mm x kg 7.52 0.78 6.26 0.94c 5.93 0.96c 6.07 0.86c
a p  0.05 vs. CS
b p 0.01 vs. CS
P 0.001 vs. CSd P 0.05 vs. 1 month RT
P 0.01 vs. I month RT
P  0.001 vs. 1 month RT
g P 0.05 vs. 1 year RT
h p
 0.01 vs. 1 year RT
P 0.001 vs. 1 year RT
attributable to a steady decline in the non-renal but not in the
renal clearance values.
The volume of distribution of prednisolone—when calculated
with reference to total or unbound prednisolone concentra-
tions—was lower one year and three to five years after trans-
plantation in the patients than in the control subjects (Table 2).
The systemic availability of total and unbound prednisolone
fluctuated somewhat, but did not show a consistent change with
time after transplantation (Table 2). About 10 times lower
plasma concentrations of prednisone than of prednisolone were
measured whether oral prednisone or i.v. prednisolone was
administered (results not shown). The AUC of prednisone after
oral prednisolone was higher in renal transplant patients than in
control subjects.
The renal clearance and the fractional renal clearance of total
and unbound prednisolone were lower in renal transplant
patients than in controls. In addition, the fraction of the steroid
dose recovered in urine as prednisolone or as prednisone was
lower in renal transplant patients than in control subjects (Table
3). The mean value of the fraction of prednisone recovered in
urine as 6/3-hydroxy-prednisolone declined as a function of time
after renal transplantation (Table 3). CsA concentrations in
whole blood were measured after oral and i.v. dosing by HPLC.
The mean total body clearance of CsA was lower one year and
three to five years after transplantation than one month after
transplantation (Table 2, Fig. 1). The systemic availability of
oral CsA decreased by about 30% in the course of the first year
of successful renal transplantation and remained constant there-
after (Table 2).
The galactose elimination capacity was measured in 28 pa-
tients one month after transplantation, in 26 patients one year
after transplantation and in 21 three to five years after trans-
plantation. The mean GEC was higher in the control subjects
than in the renal transplant patients investigated one month to
three to five years after transplantation (Table 2, Fig. 1). No
significant change in the GEC occurred after the first month of
successful renal transplantation.
Discussion
For clinical purposes, kidney function is adequately quanti-
tated by relatively simple means such as assessment of the
glomerular filtration rate. Because of the multiplicity and com-
plexity of the liver, a similarly simple, global measure of hepatic
function is still lacking. Thus, clinical parameters such as
encephalopathy or ascites, or routine laboratory values such as
plasma concentrations of bilirubin, albumin or clotting factors
are, in general, of prognostic value solely in patients with
relatively far advanced liver disease. Quantitation of the func-
tional hepatic derangement in patients with less advanced liver
disease, however, requires more complicated assessment of a
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cyte mass and to represent a prognostic index in patients with
liver failure. For instance, Ranek et a! [37] demonstrated that all
patients with fulminant liver failure exhibiting a GEC below 3.5
mg/kg/mm died. Of more prognostic value than a single GEC
determination, however, is probably the time dependent change
in GEC during repeated determinations [15]. In our own expe-
rience, patients with chronic liver disease of various etiologies
showing a steady decline of the GEC values die within months
when their GEC falls below 3.5 mg/kg/mm. Thus, repeated
determinations of the metabolism of prednisolone, CsA and
galactose following grafting appears adequate to quantitate
relevant aspects of liver function in stable renal allograft
recipients.
GEC and prednisolone catabolism have been shown to de-
crease with increasing age [20, 22]. The significant age differ-
ence between control groups and transplant patients might thus
have biased our results. Based on the reported data [20, 22],
however, the age dependent decrease in GEC and prednisolone
kinetics could only account for a small fraction of the differ-
ences between controls and transplant patients in the present
study. Thus, the impairment of hepatic functions observed in
renal allograft recipients seems by and large real.
The GEC was corrected for the (small) amount of galactose
excreted unchanged in urine. Thus, the lower GEC in our renal
transplant patients compared to controls is not attributable to a
decreased urinary excretion of galactose in the patients. A small
fraction of galactose is taken up into and metabolized by
extrahepatic tissues [15]. Theoretically, therefore, the dimin-
ished GEC in renal transplant patients might reflect impaired
extrahepatic elimination of galactose rather than impaired liver
function. However, in light of the small fraction of galactose
metabolized extrahepatically and the impaired microsomal liver
function, it seems highly probable that the decreased GEC truly
reflects diminished functioning liver cell mass in transplant
recipients.
CsA undergoes extensive metabolism, predominantly in the
liver [38—40] and metabolites, but virtually no unchanged CsA is
found in both bile and urine. P-450 3c was recently identified as
the single most important microsomal isoenzyme for CsA
metabolism in rabbit liver microsomes [41]. This rabbit isoen-
zyme appears to be homologous to the P-450 III family in
humans. It seems, therefore, reasonable to assume that the total
body clearance of CsA assessed specifically by HPLC methods
reflects in large part the hepatic activity of the P-450 III family
of microsomal enzymes.
Similarly, the liver is the main organ for the catabolism of
prednisolone and for the conversion of prednisone to the
biologically-active steroid, prednisolone, via reduction of the
11-oxo-group [13, 14]. Despite the impaired apparent conver-
sion of prednisone to prednisolone in patients with liver dys-
function, it is now clear that concentrations of total and
unbound prednisolone after administration of oral prednisone
are higher in patients with impaired liver function than in
controls [42]. This is due to the fact that in cirrhosis the
impaired conversion of prednisone to prednisolone is out-
weighed by a pronounced reduction of the metabolic clearance
of prednisolone. This decrease in metabolic clearance of pred-
nisolone is associated with a decline in the fractional clearance
of 6f3-hydroxyprednisolone (that is, the non-renal clearance of
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Fig. 1. Changes in clearance of prednisone and cyclosporin A and
galactose elimination capacity / month, 1 year and 3—5 years after
renal transplantation. The mean (± SE) are given.
set of metabolic functions. In the present investigation deter-
mination of the metabolism of prednisolone, CsA and galactose
was chosen to quantitate liver function for the following rea-
sons.
1.) Prednisolone and CsA are practically important drugs for
all renal transplant patients. Both are eliminated mainly follow-
ing metabolism by microsomal liver enzymes. The capacity of
this metabolism is reflected by the plasma clearance of pred-
nisolone and CsA. Alterations of the metabolism of these
immunosuppressive agents following grafting is of clinical rel-
evance.
2.) Galactose is physiologically converted into glucose by
non-inducible, cytosolic liver enzymes. The galactose elimina-
tion capacity has been shown to reflect the functioning hepato-
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Table 3. Urinary excretion (percentage of dose) of prednisolon
oral prednisone in renal transplant (RT) patients 1 month,
e, predn
1 year
isone and 613-hydroxyprednisolone after intravenous prednisolone and
and 3 to 5 years after transplantation and in control subjects (CS)
Control subjects
Transplant patients
I month 1 year 3—5 years
N subjects 28
After intravenous prednisolone
Prednisolone 28 7
Prednisone 2.4 0.7
6/3-hydroxyprednisolone 6.9 2.2
After oral prednisone
Prednisolone 12.5 4.4
Prednisone 1.7 0.5
6f3-hydroxyprednisolone 6.7 2.4
28 28 21
7,7 47b 79 35b 7.6 3.5"
1.0 0,5b 1.1 03b 11 02b
7.3 2.7 6.9 3.5 6.5 3.1
3.9 3.3' 3.1 l.8'
0.9 0.5" 0.9 04b 0.8 0.3"
6.1 3.1 4.7 2.5 3•4 14ad.c
a p
 0.01 vs. CSp  0.001 vs. CS
P 0.05 vs. I month RTd p  0.01 vs. I month RTP  0.05 vs. 1 year RT
unbound prednisolone multiplied by the percentage of 6/3-
hydroxyprednisolone recovered in urine), indicating that the
oxidative degradation of prednisolone is impaired, whereas the
formation of other metabolites is preserved [42]. Similar to
cirrhotic patients, in the present study renal transplant patients
exhibited higher prednisolone plasma concentrations after oral
prednisone than controls (data not shown). Moreover, the
fractional renal clearance of 6/3-hydroxyprednisolone was lower
in the transplant recipients than in control subjects, and steadily
declined following renal transplantation. These observations
further substantiate the hepatic functional derangement of renal
allograft recipients.
The cause of the observed functional hepatic alterations in
renal transplant patients remains unknown, but may include the
following:
1.) Alteration of microsomal enzyme activity due to changes
in diet, smoking habits or concomitant drug treatment. Certain
food constituents influence the activity of microsomal enzymes
[43]. Thus, alterations in food composition following successful
renal transplantation might account, at least in part, for the
decline in the activities of microsomal enzymes during the first
three to five years after transplantation. Note, however, that
none of the patients was on a restricted diet at any point of the
study. Thus, significant dietary changes are unlikely to have
occurred during the observation period. Since the number of
smokers among the patients studied and their daily tobacco
consumption were similar at one month and at three to five
years after transplantation, changes in smoking habits are
unlikely to account for the observed changes in microsomal
liver enzyme activities.
Microsomal enzyme activity is influenced by drug therapy. In
the patients studied, important changes in therapy included the
reduction of the dose of prednisone and the withdrawal of
ranitidine during the first year of successful transplantation.
However, as recently shown, ranitidine does not affect the
plasma concentrations of prednisolone after oral prednisone
[44]. In addition, the available experimental data do not support
the idea that prednisone causes auto-induction of its own
metabolism [13, 45], Similarly, studies indicating that pred-
nisone induces the catabolism of CsA are lacking. One prelim-
inary report suggests that high doses of steroids may inhibit the
metabolism of CsA (Klintmalm G., Sawe J., Lancet i:73 1, 1984;
personal communication). On the other hand, there is convinc-
ing evidence that CsA therapy does not affect the metabolism of
prednisolone [461. After the first year of successful renal
transplantation drug therapy remained virtually unchanged.
Thus, overall, it seems highly unlikely that alterations in drug
therapy were responsible for the continuous decline in the
activity of microsomal liver enzymes during the first three to
five years after transplantation.
2.) Concomitant liver disease. We can not entirely exclude
unrecognized, mild alcoholic liver disease in some patients. For
example, daily alcohol consumption was not routinely analyzed
by anamnestic exploration of the patients or by measuring
alcohol concentrations in blood. However, based on our clinical
assessment and routine laboratory tests, including determina-
tion of serum y.glutamyl-transpeptidase activity, significant
alcoholic liver disease was absent in all patients studied during
the entire observation period.
Some patients studied may have had unrecognized infectious
hepatitis. Indeed four of the 28 patients had serologic evidence
of hepatitis B infection. These four patients had decreased liver
function when compared with healthy controls, but not when
compared with the other renal transplant patients studied. This
indicates that hepatitis B infection is not a prerequisite for the
reduced liver function in renal transplant patients. It is possible
that some patients had acquired non-A, non-B-hepatitis while
being on dialysis, especially since all patients were given three
to five blood transfusions for improving future graft acceptance
[47]. For two reasons, however, non-A, non-B-hepatitis was
probably a rare phenomenon in our patient population: First,
the incidence of transmission of non-A, non-B-hepatitis by
blood transfusion is low at our institution; and second, serum
transaminases were measured at monthly intervals in our dial-
ysis unit, therefore most cases of non-A, non-B-hepatitis would
have been detected. CMV hepatitis as a cause of the impaired
liver function can be excluded, as none of the patients had an
increase in the 1gM titer against CMV in association with
elevated liver enzymes.
The total body clearance of prednisolone and CsA declined in
the course of the first three to five years after transplantation.
Therefore, the same dose of the two immunosuppressive agents
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given to the same patient may be expected to lead to higher drug
plasma levels and to exert a more pronounced immunosuppres-
sive effect at three to five years than at one month after
transplantation. Since at one month, one year and three to five
years after transplantation i.v. dosing of immunosuppressive
agents is the exception rather than the rule, this holds true only
if the systemic availability of orally administered drug remains
unchanged. For prednisolone this is indeed the case, and higher
concentrations of unbound prednisolone (that is, the biologi-
cally active form of the steroid) after a standard dose of oral
prednisone were measured at three to five years compared to
one month after transplantation. On the other hand blood
concentrations of CsA after a standard oral CsA dose were the
same at one month and at three to five years after transplanta-
tion. This is because the observed 20% decline in CsA total
body clearance was entirely compensated by a similar decline
of CsA systemic availability (Table 2).
End-stage renal failure and uremia profoundly affect func-
tions of a variety of organs and tissues [48], including that of the
liver. It has been demonstrated that: (a) in the rat, uremia
decreases the activity of some, but not all, hepatic P-450
isoenzymes [49]; (b) uremic rat serum inhibits propranolol
uptake by normal, that is, nonuremic rat liver [50];and (c) in
humans, non-renal, that is, presumably hepatic, clearance of a
variety of drugs is decreased in end-stage renal failure [5 1—56].
Therefore, it may not be too surprising that one month after
successful kidney transplantation, quantitative liver function
tests reflecting microsomal (clearance of prednisolone and CsA)
and cytosolic enzyme activities (GEC) were (still) diminished in
renal transplant patients. However, uremia-related metabolic
function disorders would be expected to recover with improv-
ing kidney function and time after successful renal transplanta-
tion. Surprisingly, the present investigation reveals that cyto-
solic liver function as assessed by GEC did not improve and
that microsomal liver function as assessed by the clearance of
prednisolone and CsA—two xenobiotics metabolized by dif-
ferent hepatic microsomal enzyme systems—further declined in
the course of the first three to five years of successful kidney
transplant maintenance. While our data are entirely compatible
with the high incidence of liver failure in renal transplant
patients reported by the European Dialysis and Transplant
Association Registration Committee, the underlying mecha-
nism(s) for the impaired liver function in renal transplant
recipients and for its steady decline following successful trans-
plantation remains to be elucidated.
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